SynCon Zika DNA vaccine: Phase I started

Inovio began a double-blind, placebo-controlled, Puerto Rican Phase I trial to evaluate 2 mg intradermal GLS-5700 in about 160 healthy volunteers. Data from Inovio’s first Phase I trial of GLS-5700 in...